Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Slides:

Advertisements

Similar presentations

Guidelines on diagnosis and treatment of pulmonary arterial hypertension by Nazzareno Galiè, Adam Torbicki, Robyn Barst, Philippe Dartevelle, Sheila Haworth,

Advertisements

The key pathways and classes of drugs that have been approved for the treatment of pulmonary arterial hypertension. The key pathways and classes of drugs.

Physiological changes in pulmonary arterial hypertension (PAH) patients which occur in response to pregnancy. Physiological changes in pulmonary arterial.

ECG: electrocardiogram; PFT: pulmonary function testing; Dlco: diffusion capacity of the lung for carbon monoxide; BGA: blood gas analysis; HRCT: high-resolution.

Diagnostic algorithm for pulmonary arterial hypertension (PAH).

a) Normal parasternal long-axis view.

Radiology assessment of pulmonary amyloidosis

Cohort identification and exclusion.

A 45-year-old with pulmonary hypertension

The effect of sequential addition of sildenafil to first-line epoprostenol on exercise capacity measured using 6-min walk distance (6MWD) in the PACES.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Diagnostic algorithm. Diagnostic algorithm. PH: pulmonary hypertension; group: clinical group; TTE: transthoracic echocardiography; PFT: pulmonary function.

The management options for chronic thromboembolic pulmonary hypertension (CTEPH) target different pathogenic manifestations in different parts of the pulmonary.

Algorithm for the diagnosis and treatment of portopulmonary hypertension (POPH). Algorithm for the diagnosis and treatment of portopulmonary hypertension.

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.

An algorithm for the early diagnosis of pulmonary arterial hypertension in systemic sclerosis. An algorithm for the early diagnosis of pulmonary arterial.

Axial computed tomography (CT) images a) at baseline and b) at a 12-month follow-up scan, in a patient with idiopathic pulmonary fibrosis (IPF). b) Note.

Computed tomography coronary angiogram from a 43-year-old female patient with pulmonary arterial hypertension, showing compression of the left coronary.

A) Pulmonary angiography, showing a stenosis in the subsegment of the 10th segmental artery (anterior view); b) the catheter is introduced into a web stenosis;

Cardiopulmonary exercise testing of a patient with chronic thromboembolic pulmonary hypertension showing fields 4, 6 and 9 of the Wasserman panel. a) Elevated.

Serial computed tomography (CT) imaging for monitoring disease progression in patients with idiopathic pulmonary fibrosis. Serial computed tomography (CT)

Association between cardiovascular disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD) on mortality. Association between.

Diagnostic applications of metabolic dysregulation in pulmonary hypertension. Diagnostic applications of metabolic dysregulation in pulmonary hypertension.

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Difference of oxygen uptake efficiency (OUE; oxygen uptake (V′O2)/minute ventilation (V′E)) plateau between a typical pulmonary arterial hypertension (PAH)

The “hallmarks of cancer” proposed by Hanahan and Weinberg [20, 21]

Diagnostic imaging of distal chronic thromboembolic pulmonary hypertension lesions. a) Ventilation/perfusion scintigraphy. b) Conventional pulmonary angiography.

Arterial oxygen saturation (SaO2) patterns during sleep in obstructive sleep apnoea (OSA) alone and the overlap syndrome. Arterial oxygen saturation (SaO2)

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Proposed screening algorithm for identification of pulmonary arterial hypertension (PAH) associated with connective tissue disease. Proposed screening.

Mean change from baseline in 6-min walking distance (6MWD) in the Chronic Thromboembolic Pulmonary Hypertension Soluble Guanylate Cyclase–Stimulator Trial.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Algorithm for the assessment of fitness to fly in chronic obstructive pulmonary disease patients. Algorithm for the assessment of fitness to fly in chronic.

Survival in patients with pulmonary arterial hypertension based on aetiology. •: congenital heart disease; ▪: collagen vascular disease; ▵: HIV-related;

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Model for the association between pathological features, physiological alterations and their association with pathological and clinical features. Model.

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

A 50-year-old male with persistent abnormality on computed tomography (CT) despite anticoagulation for 1 year. a) CT scan showing an expansile low attenuation.

Management of patients with obesity hypoventilation syndrome (OHS) from diagnosis to integrated care to modify health trajectories. Management of patients.

Distribution of mutations in sporadic and familial pulmonary arterial hypertension (PAH) and pulmonary veno-occlusive disease and/or pulmonary capillary.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Laplace's law: T = (P×r)/2h.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Kaplan–Meier plots for a) clinical worsening and b) survival in the overall population during the Chronic Thromboembolic Pulmonary Hypertension Soluble.

Example scans for a typical patient with operable chronic thromboembolic pulmonary hypertension. a) Perfusion (Q′) and b) ventilation (V′) lung scans.

Mean pulmonary arterial pressure (Ppa) as a function of cardiac output (Q) at two different levels of pulmonary vascular resistance (PVR). Mean pulmonary.

Effect of pulmonary arterial hypertension (PAH) on SF-36-measured health-related quality of life (HRQoL) measures versus the normal population and other.

A) Annual diagnosed incidence of pulmonary embolism (PE), and b) annual full incidence of chronic thromboembolic pulmonary hypertension (CTEPH) per 100 000.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Survival rates in older (>65 years) compared with younger (18–65 years) patients with idiopathic pulmonary arterial hypertension. a) Expected ( )

Effect of pulmonary arterial hypertension-specific treatment on systemic inflammation. a) Kaplan–Meyer survival curves for patients normalising their C-reactive.

Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Patient with inoperable chronic thromboembolic pulmonary hypertension showing a typical aspect of subpleural hypoperfusion at the capillary phase of pulmonary.

Distribution and change of the underlying disease in patients discharged with home mechanical ventilation (n = 854). ♦: chronic obstructive pulmonary disease;

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Relationship between pulmonary vascular obstruction (PVO) and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension (CTEPH) and.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Baseline New York Heart Association functional class (NYHA FC) predicts survival in patients with pulmonary hypertension using infused epoprostenol therapy.

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

Real-life pulmonary arterial hypertension (PAH) patient cases to reflect the importance of a collaborative approach to patient engagement. Real-life pulmonary.

Cardiac index (CI) changes from baseline following single oral doses of riociguat (Rio) compared with inhaled nitric oxide (NO) in patients with chronic.

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension. Diagnostic algorithm for chronic thromboembolic pulmonary hypertension. CT: computed thomography; CTEPH: chronic thromboembolic pulmonary hypertension; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; V/Q: ventilation/perfusion. aCT pulmonary angiography alone may miss diagnosis of chronic thromboembolic pulmonary hypertension. Nazzareno Galiè et al. Eur Respir J 2015;46:903-975 ©2015 by European Respiratory Society